Nautilus Biotechnology (NAUT) Q2 2024 earnings summary

Executive summary

• Continued progress on platform development and commercialization goals, with a focus on revolutionizing proteomics and enabling new biological insights, especially in neurodegenerative diseases.

• The company is in the collaboration phase of a three-phase commercial launch plan, targeting early access engagements in 2025 and broader commercialization thereafter.

• Nautilus Biotechnology is a development-stage life sciences company focused on creating a proteomics platform, with no commercial products or revenue to date.

• As of June 30, 2024, Nautilus had an accumulated deficit of $239.0 million and expects to continue incurring significant losses as it advances R&D and commercialization efforts.

• Strong enthusiasm from key opinion leaders and the research community following recent data presentations, particularly around proteoform analysis.

Financial highlights

• Q2 2024 operating expenses were $20.8 million, up 9% year-over-year, driven by increased R&D and G&A costs.

• Research and development expenses were $12.4 million, and general and administrative expenses were $8.4 million for the quarter.

• Net loss for Q2 2024 was $18.0 million, compared to $15.8 million in Q2 2023.

• Net loss per share was $(0.14) for Q2 2024, with weighted-average shares outstanding of 125.3 million.

• Cash, cash equivalents, and investments totaled $232.9 million as of June 30, 2024.

Outlook and guidance

• Commercial launch remains targeted for 2025, with early access and milestone achievements expected prior to full launch.

• Operating expense growth for 2024 is now expected to be 15–20%, below previous guidance of 25%.

• Cash runway is projected into the second half of 2026, including product completion, commercial buildout, and initial revenue ramp.

• The company expects to continue incurring significant and increasing expenses as it advances R&D, builds commercial infrastructure, and prepares for product launch.

• Current cash and investments are expected to fund planned operations and capital expenditures for at least the next 12 months.